Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-007-3 | CAS number: 9003-50-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Toxicity via Dermal Route
Key value determined in a GLP accredited laboratory study using the standard acute method, in accordance with OECD Guideline 402, EU Method B.3, JMAFF, 12 Nousan, Notification No 8147 and EPA OPPTS 870.1200.
The dermal LD50 value of Hepteen Base ® in Wistar rats was established to exceed 2000 mg/kg body weight.
Acute Toxicity via Oral Route
Key value determined in a GLP accredited laboratory study using the standard acute method, in accordance with OECD Guideline No. 423 (2001), EU method B1, US EPA OPPTS 870.1100 (2002) and JMAFF Guidelines (2000).
The oral LD50 of Hepteen Base ® in Wistar rats was established to exceed 2000 mg/kg body weight.
Acute Toxicity via Inhalation Route
Endpoint waived. Substance supplied liquid form and does not have the propensity to produce airborne dust. In addition physicochemical data on the test substance showed that it had a low vapour pressure and no boiling point, which indicates the liquid is not volatile consequently route of exposure to humans or the environment via the inhalation route would not be possible REACH REGULATION Annex VII COLUMN 2: SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1 - 7.14. "The study does not need to be conducted if the substance is marketed or used in a non solid or granular form." Test data has been provided for dermal and oral Acute Toxicity endpoints see sections 7.2.1 and 7.2.3 for more details.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 April 2016 to 10 May 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Study was conducted according to OECD, EU, US EPA and JMAFF test guidelines in an accredited GLP laboratory
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2001
- Deviations:
- yes
- Remarks:
- Deviations from the minimum level of daily mean relative humidity occurred. Day 10 Group 2, no observations for clinical signs performed
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- May 2008, including themost recent amendments.
- Deviations:
- yes
- Remarks:
- Deviations from the minimum level of daily mean relative humidity occurred. Day 10 Group 2, no observations for clinical signs performed.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- EPA 712-C-02-190, 2002.
- Deviations:
- yes
- Remarks:
- Deviations from the minimum level of daily mean relative humidity occurred. Day 10 Group 2, no observations for clinical signs performed.
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nousan,Notification No 8147, November 2000; including the most recent partial revisions.
- Deviations:
- yes
- Remarks:
- Deviations from the minimum level of daily mean relative humidity occurred. Day 10 Group 2, no observations for clinical signs performed.
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- pH (1% in water, indicative range) 8.0 – 7.8 (determined by Charles River Den Bosch)
Specific gravity/density 0.9130 - Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI (Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species: Rat, Wistar strain Crl:WI (Han) (outbred, SPF-Quality). Recognized by international guidelines as the recommended test system (e.g. OECD, EC).
Source: Charles River Deutschland, Sulzfeld, Germany.
Number of animals: 6 Females (nulliparous and non-pregnant). Each dose group consisted of 3 animals.
Age and body weight: Young adult animals (approx. 8-9 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex mean.
Identification: Earmark and tail mark
Health inspection At least prior to dosing. It was ensured that the animals were healthy and without any abnormality that might have affected the study integrity.
Animal Husbandry
Conditions
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 air changes/hour, and a 12-hour light/12-hour dark cycle: the photoperiod was between 07:00 and 19:00 hrs daily. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Accommodation
Group housing of 3 animals per cage in labeled Makrolon cages (MIV type; height 18 cm.) containing sterilized sawdust as bedding material (Lignocel S 8-15, JRS - J.Rettenmaier & Söhne GmbH + CO. KG, Rosenberg, Germany) and paper as cage-enrichment (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom).
Acclimatization period was at least 5 days before start of treatment under laboratory conditions.
Diet
Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Water
Free access to tap water.
Diet, water, bedding and cage enrichment evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study. - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Method: Oral gavage, using plastic feeding tubes. The test item was stirred on a magnetic stirrer during dosing.
Fasting: Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test item. Water was available ad libitum. - Doses:
- Single dose of 2000 mg/kg (2.19 mL/kg) body weight on Day 1.
- No. of animals per sex per dose:
- 2 consecutive groups of 3 female rats at 2000 mg/kg body weight
- Control animals:
- no
- Details on study design:
- The toxicity of the test item was assessed by stepwise treatment of groups of 3 females. The first group was treated at a dose level of 2000 mg/kg. The absence or presence of mortality of animals dosed at one step determined the next step, based on the test procedure defined in the guidelines. The onset, duration and severity of the signs of toxicity were taken into account for determination of the time interval between the dose groups.
The second group of animals at 2000 mg/kg was dosed one week after the first group. - Statistics:
- The LD50 cut-off value was established based on OECD guideline 423. No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).
- Preliminary study:
- No preliminary study conducted
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One animal was found dead on Day 9. No further mortality occurred.
- Clinical signs:
- Hunched posture, piloerection and/or ptosis were noted for the animals between Days 1 and 5.
- Body weight:
- Body weight loss or reduced body weight gain was noted for all animals during the first week of the study. The surviving animals gained weight between Days 1 and 15.
- Gross pathology:
- Abnormalities of the stomach (forestomach: irregular surface) and small intestines (wall: dark red discouloration) were noted for the animal that was found dead during the study, at macroscopic post mortem examination. Macroscopic examination of the other animals did not reveal any abnormalities.
- Other findings:
- None
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The oral LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 2500 mg/kg body weight. Based on these results:
-according to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments), Hepteen Base® does not have to be classified and has no obligatory labelling requirement for oral toxicity. - Executive summary:
Assessment of acute oral toxicity with Hepteen Base® in the rat (Acute Toxic Class Method).
The study was carried out based on the guidelines described in:
OECD No.423 (2001) "Acute Oral Toxicity, Acute Toxic Class Method"
Commission Regulation (EC) No 440/2008, B1 tris: "Acute Oral Toxicity, Acute Toxic Class Method" EPA, OPPTS 870.1100 (2002), "Acute Oral Toxicity"
JMAFF Guidelines (2000), including the most recent revisions.
Hepteen Base® was administered by oral gavage to two consecutive groups of three female Wistar rats at 2000 mg/kg body weight. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed on the day of death or after terminal sacrifice (Day 15).
One animal was found dead on Day 9. No further mortality occurred.
Hunched posture, piloerection and/or ptosis were noted for the animals between Days 1 and 5.
Body weight loss or reduced body weight gain was noted for all animals during the first week of the study. The surviving animals gained weight between Days 1 and 15.
Abnormalities of the stomach (forestomach: irregular surface) and small intestines (wall: dark red discouloration) were noted for the animal that was found dead during the study, at macroscopic post mortem examination.
Macroscopic examination of the other animals did not reveal any abnormalities.
The oral LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight. According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 2500 mg/kg body weight. Based on these results:
-according to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments), Hepteen Base® does not have to be classified and has no obligatory labelling requirement for oral toxicity.
Reference
Mortality Data
Test day |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Females 2000 mg/kg |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Females 2000 mg/kg |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- = no mortality
Clinical signs
Test day |
Max grade |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
|
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Females 2000 mg/kg |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Animal 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur Piloerection |
(1) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various Ptosis |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Animal 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur Piloerection |
(1) |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various Ptosis |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Animal 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur Piloerection |
(1) |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various Ptosis |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Animal 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
Skin/fur Piloerection |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
Various Ptosis |
(3) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
|
|
|
|
|
|
|
Animal 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur Piloerection |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various Ptosis |
(3) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Animal 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur Piloerection |
(1) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various Ptosis |
(3) |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- = sign not observed
Body weight (grams)
Sex/dose level |
Animal |
Day 1 |
Day 8 |
Day 15 |
FEMALES 2000 MG/KG |
1 |
159 |
58 |
194 |
|
2 |
138 |
132 |
157 |
|
3 |
158 |
132 |
172 |
|
Mean |
152 |
141 |
174 |
|
ST. Dev. |
12 |
15 |
19 |
|
N |
3 |
3 |
3 |
FEMALES 2000 MG/KG |
|
|
|
|
|
4 |
152 |
125* |
--- |
|
5 |
172 |
168 |
186 |
|
6 |
161 |
161 |
194 |
|
Mean |
162 |
151 |
190 |
|
ST. Dev. |
10 |
23 |
6 |
|
N |
3 |
3 |
2 |
* Animal was found dead on Day 9. Body weight at death: 115 gram
Macroscopic findings
Animal |
Organ |
Finding |
Day of death |
FEMALES 2000 MG/KG |
|
|
|
1 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
2 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
3 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
FEMALES 2000 MG/KG |
|
|
|
4 |
Stomach Small intestines |
Forestomach: irregular surface, Wall: discolouration, dark red. |
Spontaneous death Day 9 after treatment |
5 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
6 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- K1 - Study performed in GLP accredited laboratory to recognised OECD, EU & EPA standards.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 April 2016 to 03 May 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Study was conducted in accordance with OECD, EU, EPA and Japanese test guidelines, in compliance with GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nousan, Notification No 8147, November 2000; including the most recent partial revisions.
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species: Rat, Wistar strain, Crl:WI (Han) (outbred, SPF-Quality).
Recognized by international guidelines as the recommended test system (e.g. OECD, EC).
Source: Charles River Deutschland, Sulzfeld, Germany.
Number of animals: 5 males and 5 females (females were nulliparous and non-pregnant).
Age and body weight: Young adult animals (approx. 10 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex mean.
Identification: Tail mark with indelible ink.
Health inspection: At least prior to dosing. It was ensured that the animals were healthy and that the skin to be treated was intact and free from any abnormality.
Animal Husbandry
Conditions
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 air changes/hour, and a 12-hour light/12-hour dark cycle: the photoperiod was between 07:00 and 19:00 hrs daily. The light/dark cycle may be interrupted for study related activities. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Accommodation
Individually housed in labeled Makrolon cages (MIII type, height 18 cm.) containing sterilized sawdust as bedding material (Lignocel S 8-15, JRS - J.Rettenmaier & Söhne GmbH + CO. KG, Rosenberg, Germany) and paper as cage-enrichment (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom).
Acclimatization period was at least 5 days before start of treatment under laboratory conditions. During the acclimatization period the animals were group housed in Makrolon cages (MIV type, height 18 cm).
Diet
Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Water
Free access to tap water.
Diet, water, bedding and cage enrichment evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study. - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- Single dosage, on Day 1.
- Duration of exposure:
- 24 hours, after which dressings were removed and the skin cleaned of residual test item using tap water.
- Doses:
- 2000 mg/kg (2.19 mL/kg) body weight.
- No. of animals per sex per dose:
- males and 5 females (females were nulliparous and non-pregnant).
- Control animals:
- no
- Details on study design:
- Test Item Preparation
The test item was dosed undiluted as delivered by the Sponsor.
No correction was made for the purity/composition of the test item.
Treatment
Method Dermal application. The test item was stirred on a magnetic stirrer during application.
Clipping One day before exposure (Day -1) an area of approximately 5x7 cm on the back of each animal was clipped.
Application: The test item was applied on an area of approx. 10% of the total body surface, i.e. approx. 25 cm² for males and 18 cm² for females. The test item was held in contact with the skin with a dressing, consisting of a surgical gauze patch (Surgy 1D)*, successively covered with aluminum foil and Coban elastic bandage*. A piece of Micropore tape* was additionally used for fixation of the bandages in females only.
*. Manufacturers: Laboratoires Stella s.a., Liege, Belgium (surgical gauze) and 3M, St. Paul, Minnesota, U.S.A. (Coban & Micropore).
Frequency: Single dosage, on Day 1.
Dose level (volume): 2000 mg/kg (2.19 mL/kg) body weight.
Application period: 24 hours, after which dressings were removed and the skin cleaned of residual test item using tap water.
Observations
Mortality/Viability Twice daily.
Body weights Days 1 (pre-administration), 8 and 15.
Clinical signs At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15. The time of onset, degree and duration were recorded and the symptoms graded according to fixed scales:
Maximum grade 4: grading slight (1) to very severe (4)
Maximum grade 3: grading slight (1) to severe (3)
Maximum grade 1: presence is scored (1).
Necropsy At the end of the observation period, all animals were sacrificed by oxygen/carbon dioxide procedure and subjected to necropsy. Descriptions of all internal macroscopic abnormalities were recorded.
Evaluation
A dermal LD50 value was derived.
The results were evaluated according to:
- Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments);
- Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of items and mixtures (including all amendments). - Statistics:
- Not specified.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred.
- Clinical signs:
- Hunched posture, piloerection, quick breathing, shallow respiration, chromodacryorrhoea and/or ptosis were noted for the animals between Days 1 and 3
General erythema, erythema maculate, scales, scabs, wound and/or thickened areas were noted for the skin of the animals during the observation period. These local effects were considered not to have affected the conclusion of the study. - Body weight:
- Body weight loss or reduced body weight gain was noted for the male animals between Days 1 and 8.
The changes noted in body weight gain in females were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity. - Gross pathology:
- No abnormalities were found at macroscopic post mortem examination of the animals.
- Other findings:
- None specified
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The dermal LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight.
Based on these results, Hepteen Base® does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments). - Executive summary:
Assessment of acute dermal toxicity with Hepteen Base® in the rat. The study was carried out based on the guidelines described in:
-OECD No.402 (1987) "Acute Dermal Toxicity"
-Commission Regulation (EC) No 440/2008, B3: "Acute Toxicity (Dermal)"
-EPA, OPPTS 870.1200 (1998), "Acute Dermal Toxicity"
-JMAFF Guidelines (2000), including the most recent revisions.
Hepteen Base® was administered to five Wistar rats of each sex by a single dermal application at 2000 mg/kg body weight for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (Day 15).
No mortality occurred.
Hunched posture, piloerection, quick breathing, shallow respiration, chromodacryorrhoea and/or ptosis were noted for the animals between Days 1 and 3
Body weight loss or reduced body weight gain was noted for the male animals between Days 1 and 8.
The changes noted in body weight gain in females were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity.
No abnormalities were found at macroscopic post mortem examination of the animals.
The dermal LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight. Based on these results, Hepteen Base® does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Reference
Mortality Data
Test day |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Males 2000 MG/KG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Females 2000 MG/KG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Clinical signs
Test day |
|
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
Max grade |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Males 2000 MG/KG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANIMAL 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
2 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Scabs |
(3) |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Scabs (Flank left) |
(3) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
2 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema |
(4) |
- |
- |
- |
3 |
3 |
2 |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema maculate (treated skin) |
(4) |
- |
- |
- |
2 |
2 |
2 |
2 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scabs (Left flank) |
(3) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
Scabs (Treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Secrretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
2 |
2 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
Scabs (Flank left) |
(3) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
Scabs (treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema maculate (treated skin) |
(4) |
- |
- |
- |
3 |
3 |
2 |
2 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Scabs (Flank left) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Scabs (Treated skin) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (eye left) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Chromodacryorrhoea (eye right) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Chromodacryorrhoea (Snout) |
(3) |
- |
2 |
2 |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Scabs (treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ptosis |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
FEMALES 2000 MG/KG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANIMAL 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
2 |
2 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema maculate (Treated skin) |
(4) |
- |
- |
- |
1 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Scabs (Treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
Scabs (Treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Thickened are (Treated area) |
(3) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ptosis |
(3) |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (treated skin) |
(4) |
- |
- |
- |
1 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema maculate (Treated skin) |
(4) |
- |
- |
- |
1 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Scabs(Treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema maculate (Treated skin |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (Treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
Scabs (Treated skin) |
(3) |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Thickened are (Treated skin) |
(3) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
3 |
2 |
2 |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Erythema Maculate (Treated skin) |
(4) |
- |
- |
- |
2 |
2 |
1 |
1 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scales (treated skin) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
Thickened area (Treated skin) |
(3) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- = Sign not observed
Body weights
SEX/DOSE LEVEL |
Animal |
Day 1 |
Day 8 |
Day 15 |
Males 2000 MG/KG |
|
|
|
|
|
1 |
325 |
331 |
353 |
|
2 |
342 |
329 |
359 |
|
3 |
332 |
323 |
359 |
|
4 |
341 |
338 |
36 |
|
5 |
325 |
319 |
345 |
|
Mean |
333 |
328 |
356 |
|
ST.DEV. |
8 |
7 |
8 |
|
N |
5 |
5 |
5 |
Females 2000 MG/KG |
|
|
|
|
|
6 |
193 |
198 |
209 |
|
7 |
201 |
207 |
209 |
|
8 |
193 |
199 |
205 |
|
9 |
197 |
207 |
219 |
|
10 |
196 |
205 |
206 |
|
Mean |
196 |
203 |
210 |
|
ST.DEV. |
3 |
4 |
6 |
|
N |
5 |
5 |
5 |
Macroscopic findings
Animal |
Organ |
Finding |
Day of death |
Males 2000 MG/KG |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
1 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
2 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
3 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
4 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
5 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
Females 2000 MG/KG |
|
|
|
6 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
7 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
8 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
9 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
10 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- K1 - Study performed in GLP accredited laboratory to recognised OECD, EU & EPA standards.
Additional information
Acute Toxicity via Dermal Route
Hepteen Base® was administered to five Wistar rats of each sex by a single dermal application at 2000 mg/kg body weight for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (Day 15).
No mortality occurred.
Hunched posture, piloerection, quick breathing, shallow respiration, chromodacryorrhoea and/or ptosis were noted for the animals between Days 1 and 3
Body weight loss or reduced body weight gain was noted for the male animals between Days 1 and 8.
The changes noted in body weight gain in females were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity.
No abnormalities were found at macroscopic post mortem examination of the animals.
The dermal LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight. Based on these results, Hepteen Base® does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Acute Toxicity via Oral Route
Hepteen Base® was administered by oral gavage to two consecutive groups of three female Wistar rats at 2000 mg/kg body weight. Animals were subjected to daily
observations and weekly determination of body weight. Macroscopic examination was performed on the day of death or after terminal sacrifice (Day 15).
One animal was found dead on Day 9. No further mortality occurred.
Hunched posture, piloerection and/or ptosis were noted for the animals between Days 1 and 5.
Body weight loss or reduced body weight gain was noted for all animals during the first week of the study. The surviving animals gained weight between Days 1 and 15.
Abnormalities of the stomach (forestomach: irregular surface) and small intestines (wall: dark red discouloration) were noted for the animal that was found dead during the study, at macroscopic post mortem examination.
Macroscopic examination of the other animals did not reveal any abnormalities.
The oral LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight. According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 2500 mg/kg body weight. Based on these results:
-according to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments), Hepteen Base® does not have to be classified and has no obligatory labelling requirement for oral toxicity.
Acute Toxicity via Inhalation Route
Endpoint waived. Substance supplied liquid form and does not have the propensity to produce airborne dust. In addition physicochemical data on the test substance showed that it had a low vapour pressure and no boiling point, which indicates the liquid is not volatile consequently route of exposure to humans or the environment via the inhalation route would not be possible REACH REGULATION Annex VII COLUMN 2: SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1 - 7.14. "The study does not need to be conducted if the substance is marketed or used in a non solid or granular form." Test data has been provided for dermal and oral Acute Toxicity endpoints see sections 7.2.1 and 7.2.3 for more details.
Justification for classification or non-classification
Acute Toxicity via Dermal Route
According to the OECD 402 test guideline, the dermal LD50 value of Hepteen Base® in Wistar rats was established to exceed 2000 mg/kg body weight. Based on these results, Hepteen Base® does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Acute Toxicity via Oral Route
According to the OECD 423 test guideline, the oral LD50 cut-off value was considered to be 2500 mg/kg body weight for Hepteen Base ®. Based on these results, Hepteen Base ® does not have to be classified and has no obligatory labelling requirements for acute oral toxicity according to Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments). It does however meet the classification criteria for Acute Oral Toxicity Category 5 and as such is obligated to adhere to the labelling requirements under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2016) (including all amendments).
Acute Toxicity via Inhalation Route
Endpoint waived. Substance supplied liquid form and does not have the propensity to produce airborne dust. In addition physicochemical data on the test substance showed that it had a low vapour pressure and no boiling point, which indicates the liquid is not volatile consequently route of exposure to humans or the environment via the inhalation route would not be possible REACH REGULATION Annex VII COLUMN 2: SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1 - 7.14. "The study does not need to be conducted if the substance is marketed or used in a non solid or granular form." Test data has been provided for dermal and oral Acute Toxicity endpoints see sections 7.2.1 and 7.2.3 for more details.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.